Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Old Dominion Freight Line Inc (ODFL) vs Viatris Inc (VTRS) Price & Performance

Old Dominion Freight Line IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Old Dominion Freight Line Inc vs Viatris Inc — how do they compare? Old Dominion Freight Line Inc trades at $232.8 (market cap $48.83B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Old Dominion Freight Line Inc is far larger — about 2.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.

ODFLVTRS
Market Cap
$48.83B$20.50B
Sector
IndustrialsHealth
52-Week High
$248.73$17.59
52-Week Low
$126.29$8.74
Enterprise Value
$48.58B$32.71B
Dividend Yield
0.49%2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Old Dominion Freight Line Inc

Old Dominion Freight Line (ODFL) trades at $234.79, up 0.41% on the day, with a bullish technical signal and strong fundamental profitability. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results pending. Revenue declined to $5.5B in 2025, but net income margins remain robust at 18.46%. Analyst sentiment is mixed, with a consensus price target of $233.67 and a Hold-heavy rating distribution. Recent news highlights operational strength amid freight market improvements and competitive pressures from Amazon's expansion into LTL shipping.

ODFL presents a balanced outlook with high-quality fundamentals offset by premium valuations. Investment opportunities include industry-leading margins, debt-light balance sheet, and potential upside from freight recovery. Key risks include valuation concerns, competitive threats, and economic sensitivity. The stock's current price near consensus target suggests limited near-term upside, requiring careful entry timing.

Viatris Inc

Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.

The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.

Returns comparison

Trailing returns across standard periods

About Old Dominion Freight Line Inc

Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.

Read more on ODFL

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS